Skip to main content

Lidocaine ophthalmic Pregnancy and Breastfeeding Warnings

Brand names: Akten

Lidocaine ophthalmic Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: B

Animal studies have failed to reveal evidence of fetal harm when given subcutaneously at doses up to 50 mg/kg. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Lidocaine ophthalmic Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Yes

Comments:
-Systemic exposure is not expected.
-The effects in the nursing infant are unknown.

See references

See also

References for pregnancy information

  1. (2008) "Product Information. Akten (lidocaine ophthalmic)." Akorn Inc

References for breastfeeding information

  1. (2008) "Product Information. Akten (lidocaine ophthalmic)." Akorn Inc
  2. United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer